Key facts
- Epoch Biodesign’s last known valuation is $52.4M (Mar 2025).
- It has raised $64.1M; the latest was Later Stage VC ($12.0M) in Mar 2026.
- Notable investors include Plug and Play Tech Center, Innovate UK, BoxGroup, Tech Nation Group, Lowercarbon Capital — 30 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Epoch Biodesign
- ·The full record, as it builds
Funding rounds
No funding rounds for Epoch Biodesign are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epoch Biodesign
Operator of industrial biotechnology services intended to address the environmental and economic challenges posed by plastic waste. The company designs and develops enzymes by combining biology, artificial intelligence, and engineering capable of breaking down plastics into reusable chemicals, enabling industries to reduce plastic waste and enhance sustainability.
- Sector
- Business Products and Services (B2B)
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 56
- Website
- epochbiodesign.com/
- Ownership
- Privately Held (backing)
Epoch Biodesign doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epoch Biodesign shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epoch Biodesign in its N-PORT filings yet. We sweep new filings monthly.